Scientific commentary and technical depth on PBPK, IVIVC, mechanistic absorption modeling, and the evolving landscape of model-informed drug development.
When dose adjustment decisions involve pediatric patients, renal impairment, or rare genetic variants, empirical PK analysis often lacks the mechanistic basis to extrapolate with confidence.
Recent EMA guidance on model-informed BE has opened new pathways for sponsors willing to build strong mechanistic evidence packages.
A Level A correlation is the gold standard for dissolution-to-performance relationships, but it requires careful experimental design and rigorous validation.
Technical articles, regulatory updates, and KinetiX platform news delivered directly to your inbox.
Get in touch